US-based CytoSorbents has partnered with Converge Biotech, a critical care segment-focused pharmaceutical company, to expand sepsis and critical care treatment in India.
Through the collaboration, both companies aim to expand their reach in India’s sepsis and critical care markets.
The two companies will leverage their complementary product portfolios to address growing healthcare needs in the region.
CytoSorbents offers blood purification services for intensive care units (ICUs) and cardiac surgeries.
Its flagship product, CytoSorb, is a blood purification technology that reduces cytokine storms and inflammatory toxins. This helps prevent severe inflammation, organ failure, and death in critical illnesses.
CytoSorb, not yet approved in the US, also aids in treating acute liver disease and trauma by removing harmful substances like bilirubin and myoglobin.
It was first launched in Europe, as a cytokine adsorber approved for various uses, including liver disease, trauma, and cardiothoracic surgery. It also has US Food and Drug Administration (FDA) Emergency Use Authorization for Covid-19 treatment.
Used in 76 countries, the blood purification technology has been administered in over a quarter million treatments globally.
CytoSorbents CEO Phillip Chan said: “With our unique therapy and Converge Biotech’s local expertise, distribution capabilities, relationships within the Indian healthcare market, focused critical care sales team, complementary therapy portfolio, and market strength, we believe this partnership can help drive the growth of both companies for years to come in one of the fastest-growing critical care markets globally.”
Converge Biotech will use its critical care sales force and hospital network to accelerate CytoSorb’s market penetration in India, ensuring wider access to this life-saving therapy.
By adding CytoSorb to its portfolio, the pharmaceutical company will enhance its ICU offerings to include treatments for sepsis and other life-threatening conditions.
Together, CytoSorbents’ blood purification technology and Converge Biotech’s presence aim to expand access to critical care products across India, improving patient outcomes in hospitals and ICUs nationwide.
Converge Biotech managing director Arun Kumar Bijjala said: “Our mission has always been to provide innovative and life-saving therapies in the critical care space, and CytoSorb represents a highly impactful solution for sepsis and other critical illnesses that are major challenges for physicians in the ICU.”
CytoSorbents is also developing the DrugSorb-ATR antithrombotic removal system to reduce perioperative bleeding in high-risk surgery. The device, based on CytoSorb technology, targets blood thinners like ticagrelor, apixaban, and rivaroxaban.
